<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melasma: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melasma: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Melasma: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pearl E Grimes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Valerie D Callender, MD, FAAD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3930213029"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The management of melasma is often challenging, with incomplete responses in many cases and frequent relapses [<a href="#rid1">1,2</a>]. A combination of therapies targeting multiple pathogenic elements, such as photodamage, inflammation, aberrant vascularity, and abnormal pigmentation, generally provides the best clinical outcomes [<a href="#rid3">3</a>]. The available therapeutic armamentarium includes a variety of agents that inhibit the biosynthesis of melanin and increase epidermal turnover and chemical peels and lasers that accelerate the removal of melanin, without influencing melanin synthesis or melanosome transfer from melanocytes to keratinocytes [<a href="#rid4">4-6</a>].</p><p>This topic presents an overview of treatments for melasma that can be used as part of a comprehensive management plan that should be individualized to each patient [<a href="#rid1">1-3,7-10</a>]. The pathogenesis, clinical manifestation, and diagnosis of melasma are discussed separately. Other congenital and acquired hyperpigmentation disorders are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121155.html" rel="external">"Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p></p><p class="headingAnchor" id="H3775807400"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Pretreatment evaluation of the patient includes assessment of severity and duration of melasma, specific risk and trigger factors, level of adherence to treatment, and willingness to adopt strict photoprotection measures. Moreover, use and response to previous treatments should also be assessed. As melasma is often influenced or triggered by hormone therapies, clinicians should personalize recommendations regarding the use of hormones, based on the unique needs of each patient [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/121155.html" rel="external">"Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis", section on 'Risk and trigger factors'</a>.)</p><p class="headingAnchor" id="H3663332870"><span class="h1">PATIENT EDUCATION</span><span class="headingEndMark"> — </span>Patient education has a key role in the management of melasma. Clinicians should educate patients about the risk factors and triggers for melasma; the importance of daily use of a broadband sunscreen that protects against ultraviolet (UV), visible, and even infrared light; and the importance of consistent use of maintenance therapy to minimize the risk of recurrence [<a href="#rid3">3,8,11</a>]. (See <a class="local">'Photoprotection'</a> below.)</p><p class="headingAnchor" id="H3253299932"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>There<strong> </strong>is no standard<strong> </strong>therapy for melasma. Although several treatment guidelines and algorithms have been proposed, they are, in most cases, based on expert consensus rather than on evidence from robust, large, randomized studies [<a href="#rid7">7,9,12,13</a>]. In most cases, a multimodality approach is required, incorporating photoprotection, skin lighteners, exfoliants, antioxidants, and resurfacing procedures, based on the patient's characteristics and clinical presentation [<a href="#rid14">14</a>]. Our approach to the management of melasma is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3377181510"><span class="h2">Photoprotection</span><span class="headingEndMark"> — </span>Strict photoprotection, including sun avoidance, sun-protective clothing, and broad-spectrum sunscreens, is an essential component of all treatment and prevention regimens for melasma [<a href="#rid2">2,3,7,10,11</a>].</p><p class="headingAnchor" id="H687255626"><span class="h3">Broad-spectrum sunscreens</span><span class="headingEndMark"> — </span>We suggest daily use of a broad-spectrum sunscreen with a sun protection factor (SPF) of 50 or higher. Sunscreen should be applied in an adequate amount in the morning and reapplied every two to three hours while outdoors. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p>In a Moroccan study, 185 pregnant women in their first trimester (15 percent with a previous history of melasma and 6 percent with current melasma) were asked to apply the sunscreen every two hours [<a href="#rid15">15</a>]. Skin color stayed the same or became lighter in 79 percent of the women throughout their pregnancy, and only five women (2.7 percent) developed new-onset melasma. The authors previously reported that 53 percent of pregnant women in the same geographical area developed melasma during pregnancy. Eight of the 12 women with pre-existing melasma improved.</p><p class="headingAnchor" id="H2705502676"><span class="h3">Tinted (colored) sunscreens</span><span class="headingEndMark"> — </span>Several studies documented the role of visible light in inducing pigmentation in persons with darker skin types [<a href="#rid16">16,17</a>]. Chemical and mineral (zinc oxide- and titanium dioxide-based) broad-spectrum sunscreens do not provide optimal protection from visible light. The most efficacious visible light sunscreens contain iron oxide in concentrations above 3%. Of note, iron oxide is the major pigment used in tinted sunscreens and colored topical products and cosmetics [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p>Several studies support the use of ultraviolet (UV) <strong>and</strong> visible light protection in the treatment and prevention of melasma.</p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week, randomized trial assessed the efficacy of a broad-spectrum sunscreen with an SPF ≥50 with or without iron oxide as a visible light-absorbing pigment in 68 patients with melasma receiving 4% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> as a depigmenting treatment [<a href="#rid20">20</a>]. A greater improvement in the Melasma Area and Severity Index (MASI) score and colorimetry occurred in the group using the combination visible light and broad-spectrum sunscreen formulation compared with the group using the broad-spectrum sunscreen only.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized study performed in the spring and summer compared two identical sunscreen formulations, with the exception that one was tinted and contained iron oxide (UV plus visible light protection) and the other did not (UV light protection only) [<a href="#rid11">11</a>]. Thirty-nine patients applied the cream twice daily, with an additional application every 2 hours and 30 minutes before exposure to sunlight. Maximal reduction in the MASI score occurred in the group using the UV and visible light formulation.</p><p></p><p class="headingAnchor" id="H63758462"><span class="h2">First-line therapies</span><span class="headingEndMark"> — </span>Topical skin-lightening agents are the first-line therapy for melasma  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>). (See <a class="local">'Topical skin-lightening agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild melasma</strong> – For patients with mild melasma, we suggest <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% cream as first-line therapy. Hydroquinone can be applied to the affected areas once or twice daily for two to four months and up to six months, followed by maintenance treatment for six months or longer. (See <a class="local">'Hydroquinone'</a> below and <a class="local">'Maintenance therapy and prevention of relapse'</a> below.)</p><p></p><p class="bulletIndent1">There is considerable variation among clinicians in their prescribing practices for <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, regarding both the concentration used and the treatment duration. In the authors' experience, hydroquinone can be safely and effectively used beyond six months, if needed. In many cases, however, a rotational treatment that cycles on and off hydroquinone and non-hydroquinone skin-lightening agents seems to optimize outcomes. (See <a class="local">'Non-hydroquinone agents'</a> below.) </p><p></p><p class="bulletIndent1">Non-hydroquinone skin lighteners, such as <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a>, kojic acid, or niacinamide, alone or in combinations, can be used as alternative first-line therapies, particularly in patients who do not tolerate or have a demonstrated allergy to <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>. Of note, azelaic acid is one of a few agents that, if needed, can be used in pregnant women. (See <a class="local">'Azelaic acid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe melasma</strong> – For patients with moderate to severe melasma, the <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a>, <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, and tretinoin triple combination cream (TCC) is preferred to hydroquinone 4% cream as initial treatment  (<a class="graphic graphic_picture graphicRef127150" href="/d/graphic/127150.html" rel="external">picture 1</a>). The cream is applied nightly for two to four months. The TCC is the only US Food and Drug Administration-approved melasma treatment. (See <a class="local">'Triple combination cream'</a> below.)</p><p></p><p class="headingAnchor" id="H4237952367"><span class="h2">Second-line therapies</span><span class="headingEndMark"> — </span>Chemical peels and oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> are second-line therapies for patients with melasma that does not respond to topical therapies alone  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>). (See <a class="local">'Chemical peels'</a> below and <a class="local">'Oral agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial chemical peels</strong> – Superficial chemical peels commonly used for the treatment of melasma include glycolic acid, other alpha-hydroxy acids, salicylic acid, Jessner's peel, and <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a>  (<a class="graphic graphic_table graphicRef122600" href="/d/graphic/122600.html" rel="external">table 1</a>). Trichloroacetic acid is not marketed in the United States and Canada. Several sessions (approximately five to six) administered at two- to four-week intervals can be used as an adjunct to regular use of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> or non-hydroquinone lightening agents  (<a class="graphic graphic_table graphicRef122536" href="/d/graphic/122536.html" rel="external">table 2</a>). Because chemical peels temporarily remove epidermal melanin without affecting melanogenesis or melanocytes, patients should be aware that any improvements will probably be temporary. (See <a class="local">'Chemical peels'</a> below and  <a class="medical medical_review" href="/d/html/13632.html" rel="external">"Chemical peels: Procedures and complications"</a>.)</p><p></p><p class="bulletIndent1">Skin priming is essential to optimize outcomes with chemical peels. Priming, or preparing the skin, involves the application of topical skin-lightening agents, such as <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> and tretinoin, prior to the peeling procedure, with the aim of enhancing the effect of the chemical peel and decreasing the risk of postinflammatory hyperpigmentation [<a href="#rid21">21</a>]. Priming should be done for at least two to four weeks. Lightening agents can be continued up to the time of peeling, whereas tretinoin should be discontinued at least 7 to 10 days before the procedure. Tretinoin significantly increases the depth of dermal penetration of the peeling agent, which can lead to untoward complications. (See  <a class="medical medical_review" href="/d/html/13632.html" rel="external">"Chemical peels: Procedures and complications", section on 'Skin preparation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><strong>tranexamic acid</strong> – Oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a>, a hemostatic agent with antiplasmin activity, has shown efficacy in the treatment of melasma at an average dose of 250 mg twice daily [<a href="#rid22">22-24</a>]. However, relapses invariably occur upon discontinuing oral therapy. In the United States, 650 mg tablets are available. Patients are instructed to take one tablet daily or one-half of a tablet twice daily.</p><p></p><p class="bulletIndent1">Although the dose used in clinical studies for the treatment of melasma is considerably lower than that used to treat hemorrhagic conditions (3500 mg daily), general concerns linger regarding the safety profile, given <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a>'s propensity to induce thromboembolic phenomena [<a href="#rid10">10</a>]. Therefore, patients should be thoroughly screened for thrombotic risk factors before starting oral tranexamic acid  (<a class="graphic graphic_table graphicRef59759" href="/d/graphic/59759.html" rel="external">table 3</a>) [<a href="#rid3">3,25</a>]. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p></p><p class="headingAnchor" id="H4292223708"><span class="h2">Third-line therapies</span><span class="headingEndMark"> — </span>Lasers and light therapies are third-line therapies for melasma, appropriate for patients in whom topical treatments and often chemical peels have failed to produce adequate improvement  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>) [<a href="#rid6">6</a>]. Importantly, lasers and light sources should be used with great care and caution in individuals with darkly pigmented skin due to the risk of postinflammatory hyperpigmentation. (See <a class="local">'Lasers and light therapies'</a> below.)</p><p>Patients should be informed that lasers and light therapies are not cures for melasma. Indeed, approximately one-half of patients experience a recurrence within three to six months of the end of treatment, irrespective of the device used. Moreover, the recurrence may be associated with more intense pigmentation, which may be recalcitrant to subsequent treatment. Thus, clinicians should counsel patients about the importance of adhering to a maintenance regimen to minimize the risk of recurrence following laser or light therapy [<a href="#rid6">6</a>]. (See <a class="local">'Maintenance therapy and prevention of relapse'</a> below.)</p><p class="headingAnchor" id="H2769408651"><span class="h2">Maintenance therapy and prevention of relapse</span><span class="headingEndMark"> — </span>Routine approaches for prevention of relapse involve the aggressive use of broad-spectrum and visible light sunscreens as well as maintenance treatment with non-hydroquinone lighteners, such as <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a>, kojic acid, niacinamide, and retinoids, all of which are commonly used in the authors' practice  (<a class="graphic graphic_table graphicRef122536" href="/d/graphic/122536.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>). Additionally, intermittent use of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% cream or TCC twice weekly can be incorporated in the maintenance regimen to maintain clearance.</p><p>Despite this approach with the available armamentarium of agents, however, relapses are common. Relapses require resuming active treatment. </p><p class="headingAnchor" id="H584124478"><span class="h2">Cosmetic camouflage</span><span class="headingEndMark"> — </span>Cosmetic camouflage is a technique that uses makeup to conceal skin lesions and normalize the appearance of the skin [<a href="#rid26">26</a>]. It can mitigate the psychosocial impact of melasma and improve the patient's quality of life [<a href="#rid3">3,27,28</a>]. Anhydrous (waterproof) foundations that contain titanium dioxide, <a class="drug drug_general" data-topicid="10326" href="/d/drug information/10326.html" rel="external">zinc oxide</a>, and iron oxide provide a dual benefit, as they act as cosmetic concealers and sunscreen. Cosmetic camouflage can be used during active treatment.</p><p class="headingAnchor" id="H492381101"><span class="h1">TOPICAL SKIN-LIGHTENING AGENTS</span><span class="headingEndMark"> — </span>A large number of topical skin-lightening agents have been used for the treatment of melasma. Many of them act as tyrosinase inhibitors or interfere with other steps in melanin production and transfer  (<a class="graphic graphic_table graphicRef122536" href="/d/graphic/122536.html" rel="external">table 2</a>). Novel agents that are also used as primary or maintenance agents include combination hydroquinone-free preparations and <a class="drug drug_general" data-topicid="9313" href="/d/drug information/9313.html" rel="external">cysteamine</a> [<a href="#rid10">10</a>]. (See <a class="local">'Non-hydroquinone agents'</a> below.)</p><p class="headingAnchor" id="H765891656"><span class="h2">Hydroquinone</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> was first noted to lighten the skin in 1936 and was initially used to treat clinical hyperpigmentation in 1961 [<a href="#rid2">2</a>]. It inhibits the conversion of tyrosine to melanin by competitively inhibiting tyrosinase [<a href="#rid29">29-31</a>]. Inhibition of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis by melanocytes and increased melanosome degradation may also contribute to hydroquinone's mechanism of action [<a href="#rid3">3,5,32</a>].</p><p>Numerous <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> formulations are now available, either as monotherapy or combined with other skin-lightening agents or exfoliants, such as glycolic acid or tretinoin [<a href="#rid2">2,33</a>] (see <a class="local">'Triple combination cream'</a> below). Concentrations range from 2% or less, in over-the-counter (OTC) formulations, to 4% or more, available by prescription only [<a href="#rid2">2</a>]. Hydroquinone rapidly oxides, and tretinoin may reduce hydroquinone oxidation [<a href="#rid9">9,33</a>].</p><p class="headingAnchor" id="H423238688"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>A 2009 systematic review of 31 randomized and uncontrolled studies assessing topical treatments, chemical peels, lasers, and other therapies in Latin American patients with melasma concluded that <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% monotherapy, triple combination cream (TCC; hydroquinone 4%, tretinoin 0.05%, and <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetate 0.01%), and double combinations (eg, 4% hydroquinone and 0.1% tretinoin) were the most appropriate treatments for mild melasma, while TCC was the most appropriate first-line treatment for moderate to severe melasma [<a href="#rid7">7</a>].</p><p>A 2010 systematic review of 20 randomized trials (2125 participants) examining the efficacy of 23 treatments concluded that TCC was more effective at lightening melasma compared with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% alone or dual combinations of hydroquinone and tretinoin or hydroquinone and <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetonide [<a href="#rid34">34</a>]. However, the included studies were generally of poor quality and could not be pooled for analysis due to considerable heterogeneity.</p><p>Another meta-analysis of 36 randomized trials evaluating the efficacy of self-applied topical interventions for melasma confirmed that TCC is more effective at lightening melasma than its individual components <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> and tretinoin [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1452972808"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">Hydroquinone</a> can lighten normal skin pigmentation. However, pigment will return to normal upon discontinuation of the product [<a href="#rid36">36</a>]. Acute complications following hydroquinone application include irritation (the most common reaction), allergic contact dermatitis, postinflammatory hyperpigmentation, and hypopigmentation [<a href="#rid2">2</a>]. Patients may develop erythema and peeling after using TCC [<a href="#rid4">4</a>]. The irritation (eg, itching, burning, and stinging sensations) was generally mild [<a href="#rid2">2</a>].</p><p>Other chronic adverse events associated with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> include nail discoloration, ocular side effects, and exogenous ochronosis. Nail discoloration seems to be a result of oxidation and polymerization of byproducts due to chronic hydroquinone use. Ocular complications are rare [<a href="#rid30">30</a>]. Exogenous ochronosis typically presents as asymptomatic hyperpigmentation, erythema, papules, papulonodules, and gray-blue colloid milia on sun-exposed skin and often proves difficult to treat  (<a class="graphic graphic_picture graphicRef90021" href="/d/graphic/90021.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef111605" href="/d/graphic/111605.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef111604" href="/d/graphic/111604.html" rel="external">picture 4</a>) [<a href="#rid7">7,30</a>]. (See  <a class="medical medical_review" href="/d/html/110148.html" rel="external">"Topical skin-lightening agents: Complications of use in the nonmedical setting", section on 'Hydroquinone'</a>.)</p><p class="bulletIndent1">Despite extensive use in the United States, hydroquinone-related exogenous ochronosis is uncommon, especially compared with the number of cases in Africa [<a href="#rid37">37</a>]. The routine use of sunscreens and the relative absence of resorcinol-containing and hydroethanolic formulations (which may increase <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> absorption) in developed countries may account for these geographical differences [<a href="#rid30">30</a>]. Nevertheless, hydroquinone is banned in some African and European countries [<a href="#rid10">10</a>].</p><p></p><p>There have been concerns about a possible link between <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> and malignancies. However, hydroquinone occurs naturally in some foods, including coffee, tea, wheat, pears, and blueberries. No retrospective case series, prospective study, or epidemiologic evaluation in the United States suggests a causative link between hydroquinone and malignancies [<a href="#rid33">33</a>]. Another literature review revealed no cases of skin cancer, internal malignancies, or hepatic dysfunction related to topical hydroquinone use for skin lightening [<a href="#rid10">10</a>]. In general, hydroquinone and TCC are well tolerated and supported by a long history of use.</p><p class="headingAnchor" id="H1720857953"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">Hydroquinone</a> is contraindicated in pregnant and breastfeeding women and in patients with documented allergy.</p><p class="headingAnchor" id="H4067972419"><span class="h2">Triple combination cream</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a>, <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, and tretinoin cream, also called triple combination cream (TCC), is the only US Food and Drug Administration-approved melasma treatment [<a href="#rid38">38</a>]. The various components of the TCC have complementary effects that act synergistically to produce the clinical benefits.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">Hydroquinone</a> is a competitive tyrosinase inhibitor that inhibits the conversion of tyrosine to melanin. (See <a class="local">'Hydroquinone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical retinoids (including tretinoin, <a class="drug drug_general" data-topicid="9352" href="/d/drug information/9352.html" rel="external">adapalene</a>, and <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a>) improve melasma by promoting turnover of keratinocytes [<a href="#rid3">3</a>]. Topical retinoids may also inhibit tyrosinase as well by enhancing the penetration of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> [<a href="#rid2">2,33</a>]. However, the onset of action when retinoids are used as monotherapy is usually longer than hydroquinone, taking approximately 24 weeks for significant lightening to emerge [<a href="#rid39">39</a>]. Tretinoin is available in various doses (from 0.01 to 0.1%) and formulations (eg, creams, gels, lotions, and solutions) but is not approved in the United States as monotherapy for melasma [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical corticosteroids may directly inhibit melanogenesis by reducing production of inflammatory mediators, such as prostaglandins and leukotrienes [<a href="#rid2">2</a>]. Few studies, however, have assessed the efficacy of corticosteroids as monotherapy [<a href="#rid2">2</a>]. The topical corticosteroid in the TCC also reduces irritation induced by the other two ingredients [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H1449049400"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of the TCC for the treatment of melasma has been evaluated in randomized trials and in a systematic review [<a href="#rid34">34,40,41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 260 East Asian and Southeast Asian patients with moderate to severe melasma were treated with the TCC or <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% cream [<a href="#rid40">40</a>]. At eight weeks in the per protocol analysis, more participants in the TCC group than in the hydroquinone group had a global severity score of "none" or "mild" (64 versus 39 percent). Similar results were obtained in the intention-to-treat population (59 versus 36 percent). Adverse events were reported in 49 percent of patients in the TCC group and 14 percent of those in the hydroquinone group and included erythema, irritation, desquamation, and skin discomfort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 641 patients received the TCC or dual combination creams (tretinoin 0.05% and <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4%, tretinoin 0.05% and <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetonide 0.01%, hydroquinone 4% and fluocinolone acetonide 0.01%) twice daily for eight weeks [<a href="#rid41">41</a>]. In the TCC group, 26 percent had complete clearing of melasma compared with 9.5, 1.9, and 2.5 percent in each of the dual combination creams, respectively. Adverse effects included erythema, desquamation, burning, dryness, and pruritus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2010 systematic review of 20 randomized trials (2125 participants) examining the efficacy of 23 treatments concluded that the TCC was more effective at lightening melasma compared with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% alone or dual combinations of hydroquinone and tretinoin or hydroquinone and <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetonide [<a href="#rid34">34</a>]. The included studies were heterogeneous and generally of low quality.</p><p></p><p>Intermittent use of the TCC may be effective in preventing melasma relapse in some patients [<a href="#rid42">42,43</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 242 patients with moderate to severe melasma who had no or mild melasma after eight weeks of daily TCC treatment were assigned to a six-month maintenance treatment with the TCC in a twice-weekly or tapering regimen (three times weekly for one month, two times weekly for two months, and one time weekly for one month) [<a href="#rid42">42</a>]. At six months, 54 and 53 percent of patients were relapse-free in the two groups, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label study by the author's group, 52 patients applied the TCC daily for 12 weeks. Of these, 27 patients who were clear or almost clear at 12 weeks started maintenance therapy with the TCC twice weekly for an additional 12 weeks, while 25 patients who were not clear or almost clear at 12 weeks continued daily treatment [<a href="#rid43">43</a>]. Of the 27 patients on maintenance therapy, 21 relapsed and restarted daily treatment, and 6 remained on maintenance TCC throughout follow-up. At 24 weeks, 68 percent of patients in all groups combined were clear or had mild melasma. Scores on a 10-point patient satisfaction score (where 10 was the best) averaged approximately 9, and patients wanted to continue treatment [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H2082413732"><span class="h3">Contraindications and adverse effects</span><span class="headingEndMark"> — </span>The TCC is contraindicated in pregnant and breastfeeding women. Adverse effects include skin irritation, desquamation, and burning. Adverse effects of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> are discussed above. (See <a class="local">'Adverse effects'</a> above.)</p><p class="headingAnchor" id="H1471710177"><span class="h2">Non-hydroquinone agents</span></p><p class="headingAnchor" id="H3228397434"><span class="h3">Azelaic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">Azelaic acid</a> inhibits tyrosinase and shows antiproliferative and cytotoxic effects on several tumor cell lines in vitro [<a href="#rid5">5,36</a>]. In randomized trials, azelaic acid 20% cream has been shown to be as effective as 4% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> cream but more effective than 2% hydroquinone cream [<a href="#rid44">44,45</a>].</p><p>Skin lightening produced by <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a> typically takes one to two months to develop [<a href="#rid39">39</a>]. Between 1 and 5 percent of patients treated with 20% azelaic acid report pruritus, burning, stinging, and tingling. More rarely, patients experience erythema, dryness, rash, peeling, irritation, and dermatitis [<a href="#rid2">2</a>].</p><p>Of note, <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a> is one of the few skin-lightening agents that can be used for the treatment of melasma during pregnancy, if needed.</p><p class="headingAnchor" id="H3210368175"><span class="h3">Kojic acid</span><span class="headingEndMark"> — </span>Kojic acid is derived from a species of <em>Aspergillus</em> and <em>Penicillium</em>.<em> </em>It inhibits tyrosinase by chelating copper at the enzyme's active site. Kojic acid is widely used in Asia and is available in several OTC formulations at 2% in the United States, but when used as monotherapy, it seems to be less effective than <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> [<a href="#rid3">3,7,33</a>]. Patients who are intolerant of hydroquinone may also consider kojic acid [<a href="#rid8">8</a>].</p><p>In a 12-week, split-face study, 40 Chinese women with melasma were treated on one-half of the face with kojic acid 2% in a gel containing glycolic acid 10% and <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 2% and on the other half with a comparable formula without kojic acid [<a href="#rid46">46</a>]. Melasma improvement of ≥50 percent (based on reduction in melasma area and degree of lightening) occurred in more sides treated with kojic acid than in the control sides (60 versus 47.5 percent, respectively).</p><p>Several studies have reported that kojic acid is a sensitizer, and it has been associated with mutagenicity and contact dermatitis [<a href="#rid8">8,33</a>].</p><p class="headingAnchor" id="H1926752635"><span class="h3">Niacinamide</span><span class="headingEndMark"> — </span>Niacinamide, also known as <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a>, is the physiologically active form of <a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">niacin</a> or vitamin B3 [<a href="#rid47">47</a>]. Niacinamide blocks the transfer of melanosomes from melanocytes to keratinocytes. It has an anti-inflammatory effect and increases the biosynthesis of ceramides, as well as other stratum corneum lipids with enhanced epidermal permeability barrier function.</p><p>Several studies have documented the efficacy of niacinamide and niacinamide-based formulations for treatment of melasma. In an eight-week, left-right, randomized trial, 27 women with melasma were randomized to receive niacinamide 4% cream on one side of the face and <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% on the other [<a href="#rid48">48</a>]. The Melasma Area and Severity Index (MASI) score decreased by 70 percent from baseline in the sides treated with hydroquinone and by 62 percent in the sides treated with niacinamide. Moreover, good to excellent improvement was reported in 44 percent of patients with niacinamide and 55 percent with hydroquinone 4%. Niacinamide reduced the mast cell infiltrate and showed improvement in solar elastosis as well.</p><p class="headingAnchor" id="H79262474"><span class="h3">Rucinol</span><span class="headingEndMark"> — </span>Rucinol is a resorcinol derivative that inhibits tyrosinase and tyrosinase-related protein-1 (TRP-1), another enzyme in the melanin biosynthetic pathway. The efficacy of rucinol was assessed in a randomized, split-face trial of 32 women with melasma who applied 0.3% rucinol serum or vehicle twice daily for 12 weeks, followed by open treatment of the full face for an additional 12 weeks [<a href="#rid49">49</a>]. At 12 weeks, the mean MASI score was lower for the rucinol-treated sides than for the sides treated with vehicle (6.2 versus 6.7, respectively).</p><p class="headingAnchor" id="H2912868119"><span class="h3">Cysteamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9313" href="/d/drug information/9313.html" rel="external">Cysteamine</a> is a naturally occurring antioxidant produced during the coenzyme A metabolism cycle in all mammalian cells. The efficacy of cysteamine hydrochloride cream for the treatment of melasma has been documented in a few randomized trials [<a href="#rid50">50-52</a>]. In one trial that enrolled 50 patients treated with 5% cysteamine cream or placebo applied once daily for four months, the MASI scores and colorimetric values were lower in the cysteamine group than in the placebo group [<a href="#rid51">51</a>]. Side effects occurred in nearly all patients in the cysteamine group but were mild and included erythema, dryness, itching, burning, and irritation.</p><p class="headingAnchor" id="H16358880"><span class="h3">Undecylenoyl phenylalanine</span><span class="headingEndMark"> — </span>Undecylenoyl phenylalanine is an antagonist of alpha-melanocyte-stimulating hormone, beta-adrenergic receptors, and stem cell receptors. In a randomized study, 40 women with melasma applied topical undecylenoyl phenylalanine 2% or vehicle twice daily for 12 weeks; 37 patients completed the study [<a href="#rid53">53</a>]. Seventeen of the 20 patients using undecylenoyl had a partial response, with 11 showing a moderate improvement and 6 showing a marked improvement. No patient showed a total response. Adverse effects were mild and included erythema, itching, and burning at the application site.</p><p class="headingAnchor" id="H1318837451"><span class="h3">Tyrosinase inhibitors</span><span class="headingEndMark"> — </span>Isobutylamido thiazolyl resorcinol is a potent inhibitor of human tyrosinase. In vitro studies have shown that isobutylamido thiazolyl resorcinol has a superior depigmenting activity compared with arbutin, kojic acid, and <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> [<a href="#rid54">54,55</a>].</p><p>A randomized, split-face study assessed the efficacy of topical isobutylamido thiazolyl resorcinol 0.2% emulsion compared with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 2% or no treatment in female patients with mild to moderate facial melasma [<a href="#rid56">56</a>]. All participants applied a daily sunscreen with a sun protection factor (SPF) of 30 or higher. At 12 weeks, isobutylamido thiazolyl resorcinol induced a greater decrease of the MASI score from baseline compared with hydroquinone. Moreover, MASI improvement was noted in more isobutylamido thiazolyl resorcinol-treated sides than in hydroquinone-treated sides (79 versus 61 percent, respectively).</p><p>In another trial, twice-daily isobutylamido thiazolyl resorcinol 0.2% was compared with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% in 50 female patients [<a href="#rid57">57</a>]. At 90 days, the mean reduction of the MASI score compared with baseline was similar for isobutylamido thiazolyl resorcinol and hydroquinone (43 and 33 percent, respectively).</p><p class="headingAnchor" id="H3705353013"><span class="h3">Topical methimazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">Methimazole</a> is an oral agent commonly used to treat patients with hyperthyroidism. Studies have documented the lightening effects of a topical formulation of methimazole in female patients with melasma [<a href="#rid58">58</a>]. It has been shown to inhibit peroxidase and tyrosinase.</p><p>A randomized trial evaluated the efficacy and safety of <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> 5% once a day versus 4% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> in 50 Iranian female patients with melasma [<a href="#rid59">59</a>]. At eight weeks, the reduction of the MASI score was greater in the hydroquinone group than in the methimazole group (76 versus 25 percent, respectively). Safety studies of topical methimazole have shown no impact on serum thyroid-stimulating hormone levels [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H3285213889"><span class="h3">Topical malassezin</span><span class="headingEndMark"> — </span>Malassezin is a natural indole compound of the skin microbiome produced by <em>Malassezia furfur</em>. It is an aryl hydrocarbon receptor agonist and potent antioxidant. A proof-of-concept, 22-week, double-blind study assessed its efficacy in 20 patients with melasma and photodamage [<a href="#rid61">61</a>]. Patients were treated for 14 weeks with an oil-in-water emulsion 0.1% to 1% and observed for an additional eight weeks. Malassezin induced a significant reduction in facial hyperpigmentation noted as early as four weeks. No relapse was noted among responders, with continued improvement through week 22.</p><p class="headingAnchor" id="H138159496"><span class="h3">Combination hydroquinone-free preparations</span><span class="headingEndMark"> — </span>A combination hydroquinone-free preparation containing a variety of topical skin-lightening agents has been formulated to address the multiple pathways involved in the induction of hyperpigmentation [<a href="#rid62">62,63</a>]. These pathways include melanocyte activation, melanosome development, melanin synthesis, melanosome transfer, and keratinocyte differentiation and desquamation. It is available online and dispensed in clinicians' offices.</p><p>In a randomized trial of 43 patients with melasma or postinflammatory hyperpigmentation, a facial serum containing <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a>, tetrapeptides, plankton extracts, niacinamide, phenylethyl resorcinol, and undecylenoyl phenylalanine showed overall comparable efficacy to <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% [<a href="#rid62">62</a>]. In another 12-week study assessing a different combination formulation, a facial serum containing 3% tranexamic acid, 1% kojic acid, and 5% niacinamide reduced the hyperpigmentation in 55 Brazilian women with mild to moderate melasma (n = 48) or postinflammatory hyperpigmentation compared with baseline.</p><p class="headingAnchor" id="H3449873987"><span class="h3">Topical and intradermal tranexamic acid</span><span class="headingEndMark"> — </span>Topical preparations of <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> have been evaluated for the treatment of melasma in a few studies [<a href="#rid64">64-68</a>]. A topical 5% solution of tranexamic acid was compared with 3% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> in a 12-week, randomized trial including 100 patients with melasma [<a href="#rid64">64</a>]. Both treatments reduced the MASI score by 27 percent from baseline. Mild erythema and irritation were reported in 19 of 50 patients in the hydroquinone group and only in 3 of 50 in the tranexamic group.</p><p>Intralesional microinjection of <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> may improve local tolerability of the drug, while resulting in a deeper and more even intradermal distribution of the drug [<a href="#rid69">69</a>]. In an open study, 85 patients received weekly microinjections for 12 weeks. MASI scores significantly decreased from 13 at baseline to 9 at 8 weeks and 7.6 at 12 weeks [<a href="#rid69">69</a>]. Eight (9 percent) of 85 patients rated the improvement as good (51 to 75 percent lightening) and 65 (76.5 percent) as fair (26 to 50 percent lightening). The remainder regarded the improvement as poor. All patients tolerated microinjections well [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1167672781"><span class="h1">ORAL AGENTS</span></p><p class="headingAnchor" id="H3457120487"><span class="h2">Tranexamic acid</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> at the average dose of 250 mg twice daily is a promising adjunctive treatment for patients with melasma who do not respond to topical <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> or triple combination cream alone [<a href="#rid70">70</a>]. (See <a class="local">'Second-line therapies'</a> above.)</p><p><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a>, a hemostatic agent, is a synthetic derivative of lysine, which inhibits plasminogen from binding to its receptors expressed by keratinocytes [<a href="#rid1">1,69</a>]. This reduces ultraviolet (UV) light-induced plasmin activity and concentrations of free arachidonic acids and lowers prostaglandin production, tyrosinase activity in melanocytes, and the levels of melanocyte-stimulating hormone [<a href="#rid3">3,69</a>]. Tranexamic acid may also reduce levels of vascular endothelial growth factor (VEGF) and endothelin-1, chemical signals that promote angiogenesis, which appears to contribute to melasma pathogenesis [<a href="#rid3">3,71,72</a>]. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Antifibrinolytics and other pro-hemostatic therapies'</a>.)</p><p>Several observational studies and randomized trials have documented the efficacy of oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> for the treatment of melasma [<a href="#rid22">22-24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 561 melasma patients (91 percent female) from Singapore treated with <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> 250 mg twice daily for an average of four months, 90 percent of patients improved, 10 percent of patients experienced no improvement, and two patients showed worsening, according to the physician global assessment [<a href="#rid25">25</a>]. The response rate was higher in patients without family history of melasma compared with those with a family history (91 and 60 percent, respectively). Clinical improvement was apparent within two months of starting tranexamic acid, with a relapse rate of 27 percent. Moreover, 7 percent of patients developed adverse events, which were generally transient. One patient developed deep vein thrombosis and was later diagnosed with familial protein S deficiency, which increases the propensity to develop abnormal blood clots.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center, randomized study, 44 Hispanic patients with moderate to severe melasma were treated with 250 mg <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> twice daily or placebo [<a href="#rid22">22</a>]. After three months, the modified Melasma Area and Severity Index (MASI) scores declined by 49 and 18 percent in the tranexamic acid and placebo groups, respectively. In patients with severe melasma, the reductions were 51 and 19 percent, respectively. Three months after treatment ended, the reductions were 26 and 19 percent with tranexamic acid and placebo, respectively. No serious adverse events were seen in either group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 12-week, Indian, randomized trial that included 130 patients with facial melasma evaluated the efficacy of oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> 250 mg twice daily in combination with once-daily application of a triple combination cream (containing <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetonide 0.01%, tretinoin 0.05%, and <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 2%) compared with the triple combination cream alone [<a href="#rid73">73</a>]. At 12 weeks, more patients in the combined treatment group than in the single treatment group showed a ≥75 percent improvement in the MASI score (66 versus 27 percent, respectively). At 24 weeks, recurrence occurred in 18 percent of patients in the tranexamic acid group compared with 64 percent in the triple combination cream group. Gastrointestinal adverse events, including gastritis, nausea, and vomiting, occurred in approximately 15 percent of patients in the tranexamic acid group.</p><p></p><p>Although oral <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> has an overall good safety profile, it should be considered a second-line therapy for melasma. Adverse effects include abdominal bloating, headache, tinnitus, menstrual irregularities, and, in rare cases, deep vein thrombosis. Therefore, patients should be thoroughly screened for thrombotic risk factors before starting oral tranexamic acid [<a href="#rid3">3,25</a>]. Relapses occur upon discontinuing oral therapy.</p><p class="headingAnchor" id="H1234352715"><span class="h2"><i>Polypodium leucotomos</i></span><span class="headingEndMark"> — </span>Extracts of <em>Polypodium leucotomos</em>,<em> </em>a fern native to Central and South America, are attracting increasing attention as a possible oral treatment for melasma and other pigmentary diseases [<a href="#rid1">1,74-76</a>].<em> P. leucotomos </em>promotes expression of the <em>p53</em> suppressor gene, modulation of inflammatory cytokines, and upregulation of endogenous antioxidant systems, and it inhibits cyclooxygenase-2 (the inducible enzyme responsible for prostaglandin production) triggered by UV radiation [<a href="#rid10">10</a>].</p><p>Clinical studies of oral <em>P. leucotomos</em> have produced mixed results. A small, randomized trial including 33 Hispanic women with melasma compared 240 mg oral <em>P. leucotomos</em> extract with placebo three times daily for 12 weeks with the use of a sun protection factor (SPF) 55 sunscreen [<a href="#rid75">75</a>]. The melanin index (the difference between pigmented and adjacent normal skin measured using narrowband reflectance spectrophotometry) improved by approximately 29 and 14 percent in the <em>P. leucotomos</em> and placebo groups, respectively, between baseline and week 12. MASI scores also significantly improved in both groups. However, no statistically significant difference emerged between the groups on either outcome.</p><p><em>P. leucotomos</em> extract may hasten clinical improvements when added to <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>. A randomized study analyzed 33 Southeast Asian females receiving treatment for melasma with 4% topical hydroquinone and an SPF 50+ sunscreen plus oral <em>P. leucotomos</em> extract or placebo for 12 weeks [<a href="#rid29">29</a>]. At 12 weeks, 31 and 6 percent of the <em>P. leucotomos </em>and placebo groups, respectively, showed at least a 75 percent improvement in MASI scores. No major adverse effects of treatments were reported.</p><p>Indeed, based on a review of the literature, doses of <em>P. leucotomos </em>extract between 480 and 1200 mg daily do not seem to be associated with clinically significant adverse events [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2466919994"><span class="h2">Glutathione</span><span class="headingEndMark"> — </span>Glutathione, a tripeptide consisting of glutamate, cysteine, and glycine, has multiple actions that combine to produce a skin-whitening effect. It inhibits tyrosinase, is an endogenous antioxidant, reduces inflammation, and can skew production from black or brown eumelanin to pheomelanin, which is yellow-red [<a href="#rid3">3,77</a>]. Because the ratio between the two forms of melanin determines skin color, an increase in pheomelanin lightens skin.</p><p>The effects of 500 mg glutathione lozenge taken orally once daily for eight weeks was evaluated in an open study in 30 Filipino women [<a href="#rid77">77</a>]. Patients were evaluated every two weeks. In sun-exposed skin, the melanin index significantly and steadily decreased compared with baseline at all assessment times. Buccal glutathione also decreased the melanin index compared with baseline in sun-protected skin. Ninety percent of patients stated that buccal glutathione produced a moderate skin-lightening effect, and the remainder reported a mild effect. There were no serious adverse effects, although two participants withdrew due to sore gums and the taste and consistency of the lozenge.</p><p>A topical glutathione 2% lotion was compared with vehicle alone in a randomized, split-face study including 30 Filipino women (mean age 36) [<a href="#rid78">78</a>]. Patients applied the lotion twice daily for 10 weeks. At week 10, 67 percent of the glutathione-treated sides exhibited skin whitening compared with 3 percent of the vehicle-treated sides. Moreover, glutathione showed a rapid onset of action, with 13 percent of treated sides exhibiting skin whitening at six weeks. No adverse events related to the application of topical glutathione were reported.</p><p class="headingAnchor" id="H3640987500"><span class="h1">CHEMICAL PEELS</span><span class="headingEndMark"> — </span>Chemical peeling involves the topical application of a wounding agent, wherein the desired outcome is a controlled regeneration of the skin, depending on the depth of penetration of the specific agent used  (<a class="graphic graphic_table graphicRef122600" href="/d/graphic/122600.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef122537" href="/d/graphic/122537.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H1866705189"><span class="h2">Types of chemical peels</span><span class="headingEndMark"> — </span>Chemical peel agents remove definite skin layers (eg, superficial, medium-depth, and deep), which triggers epidermal regeneration, and are thus classified according to the histologic depth of peeling into superficial very light, superficial light, medium-depth, and deep peels  (<a class="graphic graphic_table graphicRef122600" href="/d/graphic/122600.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef122537" href="/d/graphic/122537.html" rel="external">figure 1</a>) [<a href="#rid3">3,79</a>]. The majority of clinicians using chemical peels for melasma utilize superficial or medium-depth peels. These include glycolic acid, other alpha-hydroxy acids, salicylic acid, Jessner's solution, and <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a>. Trichloroacetic acid is considered the gold standard for peeling. Trichloroacetic acid precipitates epidermal proteins, causing sloughing and necrosis of the treated area. It can be used as a superficial or medium-depth peeling agent. The extent of wounding is concentration dependent. Although trichloroacetic acid is no longer sold as a pharmaceutical in the United States, it remains available through nonpharmaceutical channels and in use globally. (See  <a class="medical medical_review" href="/d/html/121148.html" rel="external">"Chemical peels: Principles, peeling agents, and pretreatment assessment"</a> and  <a class="medical medical_review" href="/d/html/13632.html" rel="external">"Chemical peels: Procedures and complications"</a>.)</p><p class="headingAnchor" id="H1803651698"><span class="h2">Efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycolic acid</strong> – Glycolic acid is the most extensively studied peeling agent for melasma [<a href="#rid3">3,80</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a review of studies assessing the efficacy of chemical peels (including glycolic acid, lactic acid, Jessner's solution, tretinoin, and salicylic acid) for the treatment of melasma in patients with darkly pigmented skin, glycolic acid peeling was associated with a moderate response in approximately one-half of the patients, with patients having the epidermal form of melasma showing the best response [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of 40 Indian women with moderate to severe melasma, serial 30% and 40% glycolic acid peels plus daily use of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 5% and tretinoin were compared with the daily use of hydroquinone 5% and tretinoin alone. Significantly greater improvement occurred in patients treated with 30% and 40% glycolic acid peels plus daily use of the topical lightening formulation compared with daily use of only the topical formulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an eight-week, randomized study evaluating a 35% glycolic acid full-face peel alone or in combination with a 10% or 20% <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a> spot peel in 30 patients with facial melasma, the mean reduction in the Melasma Area and Severity Index (MASI) score from baseline was similar in all groups [<a href="#rid81">81</a>]. One-third of patients in the trichloroacetic acid groups experienced transient, postinflammatory hyperpigmentation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a split-face study comparing the efficacy of a peeling solution that included <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a> 20%, resorcinol 10%, and phytic acid 6% versus a glycolic acid 50% in 42 women with skin type IV or less, both treatments resulted in a 50 percent reduction of the baseline MASI score. However, adverse effects, including protracted burning and dyspigmentation, occurred in 32 and 36 percent of the sides treated with glycolic acid peel, respectively, versus none of those treated with azelaic acid 20%, resorcinol 10%, and phytic acid 6% peel [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The efficacy of a superficial peel containing glycolic acid and several other alpha-hydroxy acids combined with activated vitamin C was evaluated in a study including 21 women and 4 men aged 25 to 56 years with Fitzpatrick skin types IV or V. Patients received four chemical peels at one- to two-week intervals [<a href="#rid79">79</a>]. At eight weeks, improvement in pigmentation, pore size, and skin evenness was noted, with 96 percent of patients reporting at least fair improvement. No notable side effects or complications emerged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salicylic acid</strong> – Salicylic acid is a lipophilic, superficial peeling agent. The efficacy of 20% to 30% salicylic acid peeling has been documented by one of the authors and others in the treatment of melasma [<a href="#rid83">83,84</a>]. However, in a split-face, randomized study including 20 Latin American women with moderate to severe, bilateral melasma treated on both sides with twice-daily 4% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, the addition of 20% to 30% salicylic acid peels every two weeks for four times on one side was not more effective than hydroquinone alone in improving melasma [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichloroacetic acid</strong> – In a study of 40 female patients with a minimum MASI score of 10, <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a> 10% to 20% peels were similarly effective as glycolic acid 20% to 30% peels in reducing MASI scores [<a href="#rid86">86</a>]. Patients were peeled every two weeks. At 12 weeks, a good or very good response as assessed by patients was achieved by 75 percent of patients in the glycolic acid group and 65 percent of those in the trichloroacetic acid group, but the difference was not statistically significant.</p><p></p><p class="headingAnchor" id="H2520728871"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Possible adverse effects of chemical peels include infection, scarring (although this is rare during superficial peels), allergic reactions, milia, acneiform eruptions, persistent erythema (more than three weeks), and pigmentary changes [<a href="#rid87">87</a>]. Due to the risk of pigmentation and scarring, deep and medium-depth chemical peels should be used with caution in patients with darker skin tones [<a href="#rid7">7,21,87</a>].</p><p class="headingAnchor" id="H1632268"><span class="h1">LASERS AND LIGHT THERAPIES</span></p><p class="headingAnchor" id="H2799791078"><span class="h2">Types of lasers/light sources</span><span class="headingEndMark"> — </span>The principles dictating the use of lasers and light sources in melasma are based on the theory of selective photothermolysis. This concept proposes that the unique spectrum of light emitted by a specific laser is absorbed selectively by a cell or tissue type. Pulses of light that are brief and shorter than the thermal relaxation time of melanosomes are preferentially absorbed by pigmented structures in tissue and can cause selective heating and thermal damage to the pigmented structures [<a href="#rid88">88-90</a>]. Structures in the skin differ in the wavelengths that they absorb and the resulting thermal damage. This allows lasers to target specific chromophores, such as hair, tattoo ink, or excessive melanin, with little collateral damage to the surrounding skin [<a href="#rid6">6</a>]. Moreover, different wavelengths of light penetrate the skin to varying depths, allowing clinicians to target the particular depth of pigment in melasma  (<a class="graphic graphic_table graphicRef122621" href="/d/graphic/122621.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonablative fractional lasers</strong> – Epidermal pigmentation is most likely to respond to a 1927 nm nonablative fractional laser. Dermal melasma may be more sensitive to lasers emitting wavelengths of 1440, 1540, and 1550 nm [<a href="#rid6">6</a>]. Nonablative fractional lasers seem to be associated with the longest delay in recurrence, followed by intense pulse light (IPL) and quality-switched (QS) lasers, the last having the most rapid recurrence rate [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality-switched neodymium-doped yttrium aluminum garnet (QS Nd:YAG)</strong> – The QS Nd:YAG laser is the most commonly used laser for melasma [<a href="#rid91">91</a>], despite a relatively rapid relapse rate [<a href="#rid6">6</a>]. QS Nd:YAG lasers use a wavelength of 1064 nm, which is better absorbed by melanin than other skin structures. The QS Nd:YAG laser also damages the upper dermal vascular plexus, which is abnormal in melasma, and promotes collagen formation in the surrounding dermis [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsed dye laser (PDL)</strong> – Angiogenesis contributes to melasma pathogenesis [<a href="#rid71">71,72,92</a>]. The PDL is the gold standard for vascular lesions and, therefore, can target the vascular component of melasma [<a href="#rid92">92,93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intense pulsed light (IPL)</strong> – IPL delivers a broad spectrum of noncoherent light with a range of 500 to 1200 nm [<a href="#rid91">91</a>]. The clinician can modulate various parameters, such as wavelength and the number, duration, and delay of pulses, allowing for more accurate targeting of the chromophore. Absorption of light by melanin results in thermolysis. This forms melanin-containing "crusts" that migrate to the cornified layer of the epidermis, from where they are shed. One study reported excellent results (80 to 100 percent reduction in hyperpigmented areas and dark tones) with IPL in 47 percent of 38 patients, good results (60 to 79 percent) in 29 percent, and moderate results (40 to 59 percent) in 13 percent [<a href="#rid94">94</a>]. IPL targets all pigment in the skin and, therefore, may damage perilesional normal skin. IPL is thus not recommended in patients with darker skin tones (Fitzpatrick skin types IV through VI).</p><p></p><p class="headingAnchor" id="H1229646615"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Over the years, many studies have evaluated the effect of different laser protocols for melasma with varying results. However, most studies are small, only a few are direct comparisons with other treatments, and, as laser treatment is difficult to blind, laser studies are less robust than randomized, controlled trials [<a href="#rid2">2</a>]. Moreover, the large heterogeneity of studies of laser treatment for melasma makes drawing robust conclusions about relative efficacy and tolerability difficult [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a split-face, randomized study, 22 Thai patients received five weekly treatments with a QS Nd:YAG laser combined with 2% <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> or hydroquinone 2% alone [<a href="#rid95">95</a>]. On the laser-treated side, colorimetric relative lightness improved by 93 percent and the mean Melasma Area and Severity Index (MASI) score by 76 percent compared with 20 and 24 percent, respectively, on the control side. Three patients developed mottled hypopigmentation, four experienced rebound hyperpigmentation, and melasma recurred in all subjects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 40 patients from Korea who received 10 weekly treatments with a QS Nd:YAG laser, the mean modified MASI score decreased by 54 percent from baseline at 10 weeks. Thirty patients showed at least a fair improvement, and only four subjects showed no benefit. Two patients exhibited mottled hypopigmentation and rebound hyperpigmentation [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of microdermabrasion followed immediately by QS Nd:YAG was evaluated in 27 women with melasma that was refractory to other treatments. Patients used sunscreen and topical <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> with either tretinoin or vitamin C. On average, patients received 2.6 treatments at four-week intervals. Most patients showed more than 50 percent clearance within a month of their first treatment. At 3 to 12 months after the end of treatment, 81 percent of the patients showed more than 75 percent clearance and 40 percent showed more than 95 percent clearance. Mild post-treatment erythema after the microdermabrasion, which lasted 30 to 60 minutes, was the only adverse event observed [<a href="#rid97">97</a>].</p><p></p><p class="headingAnchor" id="H3841101664"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Worsening of hyperpigmentation or mottled hypopigmentation may occur as a result of laser therapy. Patients should be instructed to adopt rigorous sun-protective measures after treatment, including sun avoidance and daily use of sunscreen. (See <a class="local">'Photoprotection'</a> above.)</p><p class="headingAnchor" id="H3276731319"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/129725.html" rel="external">"Society guideline links: Melasma and hyperpigmentation disorders"</a>.)</p><p class="headingAnchor" id="H3131803832"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General considerations</strong> – The management of melasma is often challenging, with incomplete responses in many cases and frequent relapses. In most cases, a multimodality approach is required, incorporating photoprotection, skin lighteners, exfoliants, antioxidants, and resurfacing procedures, based on the patient's characteristics and clinical presentation. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment</strong>  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Photoprotection</strong> – For all patients with melasma, we suggest daily use of a broad-spectrum sunscreen with a sun protection factor (SPF) of 50 or higher (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Colored formulations (tinted sunscreens) containing <strong>iron oxide</strong> provide additional protection from visible light and can be used for cosmetic camouflage both during active and maintenance treatment. Sunscreen should be applied in adequate amounts in the morning and reapplied every two to three hours while outdoors. (See <a class="local">'Photoprotection'</a> above and <a class="local">'Cosmetic camouflage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild melasma</strong> – For patients with mild melasma, we suggest <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% cream as first-line therapy rather than non-hydroquinone agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Hydroquinone can be applied to the affected areas once or twice daily for two to four months and up to six months. Non-hydroquinone skin lighteners (eg, <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a>, kojic acid, niacinamide), alone or in combinations  (<a class="graphic graphic_table graphicRef122536" href="/d/graphic/122536.html" rel="external">table 2</a>), can be used as alternative first-line therapies, particularly in patients who do not tolerate or have a demonstrated allergy to hydroquinone. (See <a class="local">'First-line therapies'</a> above and <a class="local">'Hydroquinone'</a> above and <a class="local">'Non-hydroquinone agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe melasma</strong> – For patients with moderate to severe melasma, we suggest the <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a>, <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, and tretinoin triple combination cream (TCC) rather than hydroquinone 4% cream alone as initial treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The cream is applied nightly for two to four months. (See <a class="local">'First-line therapies'</a> above and <a class="local">'Triple combination cream'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemical peels</strong> – Superficial chemical peels (glycolic acid, other alpha-hydroxy acids, salicylic acid, Jessner's peel, and <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a>  (<a class="graphic graphic_table graphicRef122600" href="/d/graphic/122600.html" rel="external">table 1</a>)) are a treatment option for patients with melasma that does not respond to topical skin lightening therapies alone. Several peeling sessions (approximately five to six) at two- to four-week intervals are generally required. Regular use of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> or non-hydroquinone lightening agents should be continued between the peeling sessions  (<a class="graphic graphic_table graphicRef122536" href="/d/graphic/122536.html" rel="external">table 2</a>). (See <a class="local">'Second-line therapies'</a> above and <a class="local">'Chemical peels'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laser/light therapies</strong> – Lasers and light therapies are third-line therapies for melasma, appropriate for patients in whom topical treatments and often chemical peels have failed to produce adequate improvement  (<a class="graphic graphic_algorithm graphicRef126140" href="/d/graphic/126140.html" rel="external">algorithm 1</a>). They should be used with great care and caution, particularly in patients with darker skin to minimize the risk of postinflammatory hyperpigmentation. (See <a class="local">'Third-line therapies'</a> above and <a class="local">'Lasers and light therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995; 131:1453.</a></li><li><a class="nounderline abstract_t">Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 2009; 28:77.</a></li><li><a class="nounderline abstract_t">Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb) 2017; 7:305.</a></li><li><a class="nounderline abstract_t">Sardana K, Ghunawat S. Rationale of using hypopigmenting drugs and their clinical application in melasma. Expert Rev Clin Pharmacol 2015; 8:123.</a></li><li><a class="nounderline abstract_t">Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg 2012; 38:971.</a></li><li><a class="nounderline abstract_t">Trivedi MK, Yang FC, Cho BK. A review of laser and light therapy in melasma. Int J Womens Dermatol 2017; 3:11.</a></li><li><a class="nounderline abstract_t">Cestari T, Arellano I, Hexsel D, et al. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol 2009; 23:760.</a></li><li><a class="nounderline abstract_t">Shankar K, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb) 2014; 4:165.</a></li><li><a class="nounderline abstract_t">Sarkar R, Gokhale N, Godse K, et al. Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group. Indian J Dermatol 2017; 62:558.</a></li><li><a class="nounderline abstract_t">Grimes PE, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol 2019; 5:30.</a></li><li><a class="nounderline abstract_t">Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol 2015; 72:189.</a></li><li><a class="nounderline abstract_t">Sarma N, Chakraborty S, Poojary SA, et al. Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma. Indian Dermatol Online J 2017; 8:406.</a></li><li><a class="nounderline abstract_t">Desai SR, Alexis AF, Elbuluk N, et al. Best practices in the treatment of melasma with a focus on patients with skin of color. J Am Acad Dermatol 2024; 90:269.</a></li><li><a class="nounderline abstract_t">Huerth KA, Hassan S, Callender VD. Therapeutic Insights in Melasma and Hyperpigmentation Management. J Drugs Dermatol 2019; 18:718.</a></li><li><a class="nounderline abstract_t">Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol 2007; 21:738.</a></li><li><a class="nounderline abstract_t">Kohli I, Chaowattanapanit S, Mohammad TF, et al. Synergistic effects of long-wavelength ultraviolet A1 and visible light on pigmentation and erythema. Br J Dermatol 2018; 178:1173.</a></li><li><a class="nounderline abstract_t">Austin E, Geisler AN, Nguyen J, et al. Visible light. Part I: Properties and cutaneous effects of visible light. J Am Acad Dermatol 2021; 84:1219.</a></li><li><a class="nounderline abstract_t">Geisler AN, Austin E, Nguyen J, et al. Visible light. Part II: Photoprotection against visible and ultraviolet light. J Am Acad Dermatol 2021; 84:1233.</a></li><li><a class="nounderline abstract_t">Lyons AB, Trullas C, Kohli I, et al. Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens. J Am Acad Dermatol 2021; 84:1393.</a></li><li><a class="nounderline abstract_t">Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed 2014; 30:35.</a></li><li><a class="nounderline abstract_t">Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. J Cutan Aesthet Surg 2012; 5:247.</a></li><li><a class="nounderline abstract_t">Del Rosario E, Florez-Pollack S, Zapata L Jr, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol 2018; 78:363.</a></li><li><a class="nounderline abstract_t">Colferai MMT, Miquelin GM, Steiner D. Evaluation of oral tranexamic acid in the treatment of melasma. J Cosmet Dermatol 2019; 18:1495.</a></li><li><a class="nounderline abstract_t">Zhang L, Tan WQ, Fang QQ, et al. Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis. Biomed Res Int 2018; 2018:1683414.</a></li><li><a class="nounderline abstract_t">Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol 2016; 75:385.</a></li><li><a class="nounderline abstract_t">Antoniou C, Stefanaki C. Cosmetic camouflage. J Cosmet Dermatol 2006; 5:297.</a></li><li><a class="nounderline abstract_t">Kornhaber R, Visentin D, Thapa DK, et al. Cosmetic camouflage improves quality of life among patients with skin disfigurement: A systematic review. Body Image 2018; 27:98.</a></li><li><a class="nounderline abstract_t">Levy LL, Emer JJ. Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review. Clin Cosmet Investig Dermatol 2012; 5:173.</a></li><li><a class="nounderline abstract_t">Goh CL, Chuah SY, Tien S, et al. Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study. J Clin Aesthet Dermatol 2018; 11:14.</a></li><li><a class="nounderline abstract_t">Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006; 20:781.</a></li><li><a class="nounderline abstract_t">Lai X, Wichers HJ, Soler-Lopez M, Dijkstra BW. Structure of Human Tyrosinase Related Protein 1 Reveals a Binuclear Zinc Active Site Important for Melanogenesis. Angew Chem Int Ed Engl 2017; 56:9812.</a></li><li><a class="nounderline abstract_t">Taghavi F, Banihashemi M, Zabolinejad N, et al. Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma. J Cosmet Dermatol 2019; 18:870.</a></li><li><a class="nounderline abstract_t">Kindred C, Okereke U, Callender V. Skin-lightening agents: An overview of prescription, office-dispensed, and over-the-counter products. Cosmetic Dermatology 2013; :18.</a></li><li><a class="nounderline abstract_t">Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev 2010; :CD003583.</a></li><li><a class="nounderline abstract_t">Pennitz A, Kinberger M, Avila Valle G, et al. Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials. Br J Dermatol 2022; 187:309.</a></li><li><a class="nounderline abstract_t">Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol 2011; 10:282.</a></li><li><a class="nounderline abstract_t">Sagoe D, Pallesen S, Dlova NC, et al. The global prevalence and correlates of skin bleaching: a meta-analysis and meta-regression analysis. Int J Dermatol 2019; 58:24.</a></li><li class="breakAll">Tri-luma cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%). US FDA approved product information; Fort Worth, TX: Galderma Laboratories; January 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021112s006lbl.pdf (Accessed on November 29, 2022).</li><li><a class="nounderline abstract_t">Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutical approaches in melasma. Dermatol Clin 2007; 25:337.</a></li><li><a class="nounderline abstract_t">Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008; 159:697.</a></li><li><a class="nounderline abstract_t">Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72:67.</a></li><li><a class="nounderline abstract_t">Arellano I, Cestari T, Ocampo-Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. J Eur Acad Dermatol Venereol 2012; 26:611.</a></li><li><a class="nounderline abstract_t">Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol 2010; 62:962.</a></li><li><a class="nounderline abstract_t">Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30:893.</a></li><li><a class="nounderline abstract_t">Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989; 143:58.</a></li><li><a class="nounderline abstract_t">Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999; 25:282.</a></li><li><a class="nounderline abstract_t">Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002; 147:20.</a></li><li><a class="nounderline abstract_t">Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatol Res Pract 2011; 2011:379173.</a></li><li><a class="nounderline abstract_t">Khemis A, Kaiafa A, Queille-Roussel C, et al. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermatol 2007; 156:997.</a></li><li><a class="nounderline abstract_t">Kasraee B, Mansouri P, Farshi S. Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula. J Cosmet Dermatol 2019; 18:293.</a></li><li><a class="nounderline abstract_t">Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol 2015; 173:209.</a></li><li><a class="nounderline abstract_t">Karrabi M, David J, Sahebkar M. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study. Skin Res Technol 2021; 27:24.</a></li><li><a class="nounderline abstract_t">Katoulis A, Alevizou A, Soura E, et al. A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. J Cosmet Dermatol 2014; 13:86.</a></li><li><a class="nounderline abstract_t">Mann T, Gerwat W, Batzer J, et al. Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different from Mushroom Tyrosinase. J Invest Dermatol 2018; 138:1601.</a></li><li><a class="nounderline abstract_t">Mann T, Scherner C, Röhm KH, Kolbe L. Structure-Activity Relationships of Thiazolyl Resorcinols, Potent and Selective Inhibitors of Human Tyrosinase. Int J Mol Sci 2018; 19.</a></li><li><a class="nounderline abstract_t">Arrowitz C, Schoelermann AM, Mann T, et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol 2019; 139:1691.</a></li><li><a class="nounderline abstract_t">Lima PB, Dias JAF, Cassiano DP, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol 2021; 35:1881.</a></li><li><a class="nounderline abstract_t">Cassiano DP, Espósito ACC, da Silva CN, et al. Update on Melasma-Part II: Treatment. Dermatol Ther (Heidelb) 2022; 12:1989.</a></li><li><a class="nounderline abstract_t">Gheisari M, Dadkhahfar S, Olamaei E, et al. The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial. J Cosmet Dermatol 2020; 19:167.</a></li><li><a class="nounderline abstract_t">Kasraee B, Safaee Ardekani GH, Parhizgar A, et al. Safety of topical methimazole for the treatment of melasma. Transdermal absorption, the effect on thyroid function and cutaneous adverse effects. Skin Pharmacol Physiol 2008; 21:300.</a></li><li><a class="nounderline abstract_t">Grimes PE, Bhawan J, Howell MD, et al. A novel proof-of-concept study assessing the lightening effects and safety of malassezin for treatment of facial hyperpigmentation. J Am Acad Dermatol 2022; 87:456.</a></li><li><a class="nounderline abstract_t">Makino ET, Kadoya K, Sigler ML, et al. Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations. J Drugs Dermatol 2016; 15:1562.</a></li><li><a class="nounderline abstract_t">Desai S, Ayres E, Bak H, et al. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation. J Drugs Dermatol 2019; 18:454.</a></li><li><a class="nounderline abstract_t">Janney MS, Subramaniyan R, Dabas R, et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg 2019; 12:63.</a></li><li><a class="nounderline abstract_t">Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther 2012; 14:150.</a></li><li><a class="nounderline abstract_t">Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci 2014; 19:753.</a></li><li><a class="nounderline abstract_t">Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study. J Dermatolog Treat 2016; 27:373.</a></li><li><a class="nounderline abstract_t">Atefi N, Dalvand B, Ghassemi M, et al. Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma. Dermatol Ther (Heidelb) 2017; 7:417.</a></li><li><a class="nounderline abstract_t">Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 2006; 32:626.</a></li><li><a class="nounderline abstract_t">Wang JV, Jhawar N, Saedi N. Tranexamic Acid for Melasma: Evaluating the Various Formulations. J Clin Aesthet Dermatol 2019; 12:E73.</a></li><li><a class="nounderline abstract_t">Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous Pathology of Melasma and Its Clinical Implications. Int J Mol Sci 2016; 17.</a></li><li><a class="nounderline abstract_t">Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci 2007; 46:111.</a></li><li><a class="nounderline abstract_t">Minni K, Poojary S. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. J Eur Acad Dermatol Venereol 2020; 34:2636.</a></li><li><a class="nounderline abstract_t">Nestor M, Bucay V, Callender V, et al. Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders. J Clin Aesthet Dermatol 2014; 7:13.</a></li><li><a class="nounderline abstract_t">Ahmed AM, Lopez I, Perese F, et al. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol 2013; 149:981.</a></li><li><a class="nounderline abstract_t">Kohli I, Shafi R, Isedeh P, et al. The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study. J Am Acad Dermatol 2017; 77:33.</a></li><li><a class="nounderline abstract_t">Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Int J Dermatol 2016; 55:153.</a></li><li><a class="nounderline abstract_t">Watanabe F, Hashizume E, Chan GP, Kamimura A. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women. Clin Cosmet Investig Dermatol 2014; 7:267.</a></li><li><a class="nounderline abstract_t">Kim WS. Efficacy and safety of a new superficial chemical peel using alpha-hydroxy acid, vitamin C and oxygen for melasma. J Cosmet Laser Ther 2013; 15:21.</a></li><li><a class="nounderline abstract_t">Sharad J. Glycolic acid peel therapy - a current review. Clin Cosmet Investig Dermatol 2013; 6:281.</a></li><li><a class="nounderline abstract_t">Garg S, Thami GP, Bhalla M, et al. Comparative Efficacy of a 35% Glycolic Acid Peel Alone or in Combination With a 10% and 20% Trichloroacetic Acid Spot Peel for Melasma: A Randomized Control Trial. Dermatol Surg 2019; 45:1394.</a></li><li><a class="nounderline abstract_t">Faghihi G, Taheri A, Shahmoradi Z, Nilforoushzadeh MA. Solution of Azelaic Acid (20%), Resorcinol (10%) and Phytic Acid (6%) Versus Glycolic Acid (50%) Peeling Agent in the Treatment of Female Patients with Facial Melasma. Adv Biomed Res 2017; 6:9.</a></li><li><a class="nounderline abstract_t">Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25:18.</a></li><li><a class="nounderline abstract_t">Fabbrocini G, De Vita V, Marasca C, et al. Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement. Skin Res Technol 2013; 19:466.</a></li><li><a class="nounderline abstract_t">Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol 2010; 63:1030.</a></li><li><a class="nounderline abstract_t">Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma. Indian J Dermatol Venereol Leprol 2010; 76:447.</a></li><li><a class="nounderline abstract_t">Azzam OA, Leheta TM, Nagui NA, et al. Different therapeutic modalities for treatment of melasma. J Cosmet Dermatol 2009; 8:275.</a></li><li><a class="nounderline abstract_t">Attwa E, Khater M, Assaf M, Haleem MA. Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study. Int J Dermatol 2015; 54:235.</a></li><li><a class="nounderline abstract_t">Goldberg DJ. Laser treatment of pigmented lesions. Dermatol Clin 1997; 15:397.</a></li><li><a class="nounderline abstract_t">Anderson RR, Margolis RJ, Watenabe S, et al. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 1989; 93:28.</a></li><li><a class="nounderline abstract_t">Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg 2012; 5:93.</a></li><li><a class="nounderline abstract_t">Passeron T. Long-lasting effect of vascular targeted therapy of melasma. J Am Acad Dermatol 2013; 69:e141.</a></li><li><a class="nounderline abstract_t">Li JY, Geddes ER, Robinson DM, Friedman PM. A review of melasma treatment focusing on laser and light devices. Semin Cutan Med Surg 2016; 35:223.</a></li><li><a class="nounderline abstract_t">Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. Aesthetic Plast Surg 2010; 34:486.</a></li><li><a class="nounderline abstract_t">Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg 2010; 36:76.</a></li><li><a class="nounderline abstract_t">Choi JE, Lee DW, Seo SH, et al. Low-fluence Q-switched Nd:YAG laser for the treatment of melasma in Asian patients. J Cosmet Dermatol 2018; 17:1053.</a></li><li><a class="nounderline abstract_t">Kauvar AN. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med 2012; 44:117.</a></li></ol></div><div id="topicVersionRevision">Topic 6621 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492140" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Melasma. Etiologic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608057" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of hyperpigmentation in darker racial ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28726212" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Melasma: an Up-to-Date Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25474082" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rationale of using hypopigmenting drugs and their clinical application in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22583339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Advances in the treatment of melasma: a review of the recent literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492049" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A review of laser and light therapy in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646135" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Melasma in Latin America: options for therapy and treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25269451" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence-based treatment for melasma: expert opinion and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29263529" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30809577" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New oral and topical approaches for the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443629" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29204385" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748556" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Best practices in the treatment of melasma with a focus on patients with skin of color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31424704" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapeutic Insights in Melasma and Hyperpigmentation Management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17567299" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877342" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Synergistic effects of long-wavelength ultraviolet A1 and visible light on pigmentation and erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640508" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Visible light. Part I: Properties and cutaneous effects of visible light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640513" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Visible light. Part II: Photoprotection against visible and ultraviolet light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32335182" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313385" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378706" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chemical peels for melasma in dark-skinned patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987494" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30536592" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of oral tranexamic acid in the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30533427" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206758" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716248" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cosmetic camouflage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30212716" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cosmetic camouflage improves quality of life among patients with skin disfigurement: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152694" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606995" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16898897" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety of hydroquinone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28661582" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Structure of Human Tyrosinase Related Protein 1 Reveals a Binuclear Zinc Active Site Important for Melanogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30105847" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Skin-lightening agents: An overview of prescription, office-dispensed, and over-the-counter products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614435" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Interventions for melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35290681" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22151936" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29888464" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The global prevalence and correlates of skin bleaching: a meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29888464" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The global prevalence and correlates of skin bleaching: a meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662899" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Therapeutical approaches in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616780" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12889718" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21623930" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398959" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1816137" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2528260" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417583" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100180" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822427" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17388924" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537063" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251767" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32585079" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24910270" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427586" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different from Mushroom Tyrosinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29495618" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Structure-Activity Relationships of Thiazolyl Resorcinols, Potent and Selective Inhibitors of Human Tyrosinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30825454" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33988887" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35906506" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Update on Melasma-Part II: Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31102345" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667842" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of topical methimazole for the treatment of melasma. Transdermal absorption, the effect on thyroid function and cutaneous adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34678236" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A novel proof-of-concept study assessing the lightening effects and safety of malassezin for treatment of facial hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28095579" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31141852" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31057273" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22506692" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422661" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Topical tranexamic acid as a promising treatment for melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526300" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28748406" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16706756" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31531176" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tranexamic Acid for Melasma: Evaluating the Various Formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240341" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Heterogeneous Pathology of Melasma and Its Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363223" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The vascular characteristics of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32567734" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24688621" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740292" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28341348" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26148180" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25378941" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23368684" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Efficacy and safety of a new superficial chemical peel using alpha-hydroxy acid, vitamin C and oxygen for melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399880" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Glycolic acid peel therapy - a current review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31464703" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Comparative Efficacy of a 35% Glycolic Acid Peel Alone or in Combination With a 10% and 20% Trichloroacetic Acid Spot Peel for Melasma: A Randomized Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28299301" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Solution of Azelaic Acid (20%), Resorcinol (10%) and Phytic Acid (6%) Versus Glycolic Acid (50%) Peeling Agent in the Treatment of Female Patients with Facial Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935087" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23527534" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889235" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20657143" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958431" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Different therapeutic modalities for treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266556" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189677" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Laser treatment of pigmented lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2746004" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23060704" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lasers for treatment of melasma and post-inflammatory hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23957991" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Long-lasting effect of vascular targeted therapy of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918005" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A review of melasma treatment focusing on laser and light devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20225000" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Melasma treated with intense pulsed light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20298254" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280474" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Low-fluence Q-switched Nd:YAG laser for the treatment of melasma in Asian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22334295" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
